Leadgene Biosolutions, Inc., (Formerly CYTENA BPS), Announces Corporate Rebranding to Mark a New Phase of Growth within the Leadgene Group

Contributed by: PR Newswire

Tags

LeadgeneBiosolutions

More Like This

Leadgene Biosolutions Expands Its Product Portfolio Following Strategic Integration, Advancing Early-Stage Mixing and Long-Term Metabolic Insight

Business Wire associated0

Biocytogen Enters into Agreement with Merck, KGaA, Darmstadt, Germany to Advance Antibody-Conjugated Lipid-Based Delivery Solutions

Biocytogen Enters Collaboration with ABL Bio to Develop New Bispecific Antibody-Drug Conjugates

Biocytogen Enters into Multi-Target Antibody Agreement with Neurocrine Biosciences

Biocytogen Enters into Antibody Licensing Agreement with BeOne Medicines to Accelerate Innovative Drug Development

Biocytogen and Sihuan Pharmaceutical Announce Strategic Partnership in Weight Loss and Beyond

(Graphic: Business Wire)

Biocytogen Launches RenBiologics, A Sub-Brand Focused on Out-Licensing Fully Human Antibodies For Therapeutic Development

PR Newswire associated0

BioCina Acquires the Exclusive CDMO Rights for Leading-Edge Minicircle DNA Technology Platform from CelluTx